EVgo Posts Strong FY25 but 2026 Guidance Miss Reinforces DeepValue's Wait Rating

What happened

EVgo reported 49% year-over-year revenue growth in FY25, achieving positive adjusted EBITDA of $25 million in Q4 and improving gross margins to 46%, with a solid cash position of $151 million against $204 million in long-term debt. However, the company's 2026 revenue guidance of $410 million to $470 million falls short of consensus estimates, and management has framed the year as a 'transition' expecting acceleration in the second half. This guidance miss highlights ongoing execution risks, as EVgo remains structurally loss-making with negative free cash flow and high capital intensity, according to the DeepValue report. The report rates EVgo as 'WAIT' due to unresolved profitability challenges, dilution risks, and dependence on DOE loan draws amidst competitive and policy headwinds. Despite operational improvements, the disparity between optimistic framing and underlying financial fragility underscores the need for cautious investor scrutiny.

Implication

The lower 2026 revenue guidance signals management's previous optimism may be overstated, introducing new uncertainty around growth trajectories and breakeven timelines. Positive adjusted EBITDA in Q4 is a step forward, but sustained profitability is not assured given EVgo's history of losses, negative free cash flow, and macro challenges like slower EV adoption. Cash reserves provide a temporary buffer, but debt obligations and DOE loan covenants could strain finances if utilization stalls or expansion delays occur. DeepValue's attractive entry point of $2.25 remains relevant, as current prices near $3 do not adequately discount the risks of equity dilution or covenant stress in a bear scenario. Monitoring quarterly EBITDA trends, DOE drawdowns, and utilization metrics over the next 6-12 months is essential to validate the path to profitability before considering an investment.

Thesis delta

The new article confirms progress toward breakeven with positive Q4 adjusted EBITDA, aligning with DeepValue's base case of near-breakeven by late 2026. However, the 2026 guidance miss and transition year framing introduce incremental execution risks, keeping the core thesis unchanged at 'WAIT' due to unresolved profitability and funding challenges. No shift in valuation or probability scenarios is warranted; investors should still await two consecutive quarters of ≥$100 million revenue with breakeven-adjusted EBITDA and no equity issuance before reconsidering the rating.